Pneumonia, Ventilator-Associated Clinical Trial
Official title:
Bilateral Bronchoalveolar Lavage Cultures for Diagnosing Ventilator-associated Pneumonia. Microbiologic Concordance and Impact on the Efficacy of Treatment Decisions.
Verified date | August 2015 |
Source | Catholic University of the Sacred Heart |
Contact | n/a |
Is FDA regulated | No |
Health authority | Italy: Ethics Committee |
Study type | Interventional |
The purpose of this study is to assess microbiologic concordance rates between right- and left-lung bronchoalveolar lavage cultures from patients with suspected ventilator-associated pneumonia, identify predictors of concordance, and evaluate the impact of discordant microbiology on clinicians' ability to prescribe appropriate antibiotic treatments, the investigators conducted a prospective observational study in the general intensive care unit of a large university hospital.
Status | Completed |
Enrollment | 79 |
Est. completion date | July 2014 |
Est. primary completion date | July 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - invasive mechanical ventilation of = 48 hours - clinically suspected pneumonia (simplified Clinical Pulmonary Infectious Score exceeded 6 or chest radiographs with a new or progressive pulmonary infiltrate in a patient with at least two of the following: purulent respiratory secretions, temperature >38°C or <36°C, white blood cell count >12,000/mm3 or <4,000/mm3) Exclusion Criteria: - age <18 years - pregnancy - absence of informed consent - an arterial oxygen partial pressure to inspired oxygen fraction ratio (PaO2:FiO2) of =150 - use of positive end-expiratory pressure (PEEP) >10 cmH2O - active uncontrolled bronchospasm - unstable angina or recent (<6 weeks) myocardial infarction - unstable arrhythmia - intracranial hypertension - platelet count =20,000/mm3 - international normalized ratio (INR) or activated partial thromboplastin time (aPTT) ratio >1.5 - documented treatment-limitation orders in the patient's chart |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Catholic University of the Sacred Heart |
Butler KL, Best IM, Oster RA, Katon-Benitez I, Lynn Weaver W, Bumpers HL. Is bilateral protected specimen brush sampling necessary for the accurate diagnosis of ventilator-associated pneumonia? J Trauma. 2004 Aug;57(2):316-22. — View Citation
Esperatti M, Ferrer M, Theessen A, Liapikou A, Valencia M, Saucedo LM, Zavala E, Welte T, Torres A. Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med. 2010 Dec 15;1 — View Citation
Jackson SR, Ernst NE, Mueller EW, Butler KL. Utility of bilateral bronchoalveolar lavage for the diagnosis of ventilator-associated pneumonia in critically ill surgical patients. Am J Surg. 2008 Feb;195(2):159-63. — View Citation
Marquette CH, Herengt F, Saulnier F, Nevierre R, Mathieu D, Courcol R, Ramon P. Protected specimen brush in the assessment of ventilator-associated pneumonia. Selection of a certain lung segment for bronchoscopic sampling is unnecessary. Chest. 1993 Jan;1 — View Citation
Meduri GU, Chastre J. The standardization of bronchoscopic techniques for ventilator-associated pneumonia. Chest. 1992 Nov;102(5 Suppl 1):557S-564S. Review. — View Citation
Meduri GU, Reddy RC, Stanley T, El-Zeky F. Pneumonia in acute respiratory distress syndrome. A prospective evaluation of bilateral bronchoscopic sampling. Am J Respir Crit Care Med. 1998 Sep;158(3):870-5. — View Citation
Zaccard CR, Schell RF, Spiegel CA. Efficacy of bilateral bronchoalveolar lavage for diagnosis of ventilator-associated pneumonia. J Clin Microbiol. 2009 Sep;47(9):2918-24. doi: 10.1128/JCM.00747-09. Epub 2009 Jul 15. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Comparison of antibiotic regimens chosen on the basis of right or left-lung culture results alone with regimens chosen on the basis of bilateral culture results, by performing a simulated prescribing experiment. | For each enrolled patient, actual treatment decisions are made by the ICU attending physicians in charge of the case on the basis of the results of bilateral BAL culture and sensitivity analyses. Later, at the end of the study, data for patients with discordant BAL cultures are reviewed in a simulated prescribing session by a second team composed of an ICU physician and an infectious disease specialist. The team is asked to propose an appropriate antimicrobial regimen based on the culture and in vitro antimicrobial susceptibility data for the right-lung BAL sample alone, the left-lung BAL sample alone, and the right and left BAL samples. Each microbiological report is presented separately to the team with a summary of the patient's relevant clinical data. The prescribed regimen is defined as appropriate if it provides active coverage for all of the organisms identified in both BAL specimens. | At 18 months after study initiation | No |
Primary | Rate of microbiologic concordance between the right- and left-lung samples | Pneumonia is microbiologically confirmed when the quantitative culture of one or both BAL specimens is positive at significant growth for at least one potential bacterial pathogen. Right and left BAL cultures are classified as concordant when both are positive for the same organism(s) or when neither show any growth. Cultures are classified as discordant when at least one of the microorganisms isolated from one specimen is not recovered from the contralateral specimen. | After at least 48 hours of invasive mechanical ventilation | No |
Secondary | Possible association between purulent secretions and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between duration of mechanical ventilation and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between duration of ICU stay and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between duration of hospital stay and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between immunosuppression and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between antibiotic treatment and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between radiological infiltrate and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between body temperature and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between WBC count and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between PaO2:FiO2 and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between PEEP and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between CPIS and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between type of humidification and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between procalcitonin and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No | |
Secondary | Possible association between C-reactive protein and microbiologic concordance between right- and left-lung BAL cultures | At an expected average of 48 hours after bronchoscopy | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06370598 -
Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia
|
Phase 1/Phase 2 | |
Terminated |
NCT02806141 -
Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates
|
Phase 3 | |
Completed |
NCT01765530 -
Efficacy Study of a Novel Device to Clean the Endotracheal Tube
|
N/A | |
Completed |
NCT00521677 -
Comparison Between Two Methods of Oral Care on the Incidence of VAP
|
N/A | |
Completed |
NCT00529776 -
Prophylaxis of Ventilator Associated Pneumonia by Continuous Lateral Rotation Therapy
|
N/A | |
Completed |
NCT03401463 -
Assesment of the Endotracheal Tube Cuff Pressure Values in ICU Pateints Before and After Training Seminar
|
N/A | |
Completed |
NCT02950519 -
Endotracheal Tube Cuff Pressures in Ventilated Patients
|
N/A | |
Completed |
NCT01875692 -
Can we Better Understand the Development of VAP and Eventually Predict and Prevent it?
|
N/A | |
Completed |
NCT00515034 -
A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
|
Phase 2 | |
Recruiting |
NCT05117125 -
Biomarkers for Ventilator-associated Pneumonia
|
||
Completed |
NCT04755972 -
Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2
|
N/A | |
Terminated |
NCT02940626 -
Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.
|
Phase 2 | |
Completed |
NCT01577862 -
Colistin and Rifampicin for MDR-Acinetobacter
|
Phase 3 | |
Completed |
NCT00572559 -
Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus
|
Phase 4 | |
Withdrawn |
NCT04566172 -
Preoperative Optimization to Improve Functional Status
|
N/A | |
Recruiting |
NCT04215692 -
Lung Ultrasound-guided Fluid Therapy in Pediatric Intensive Care Unit Patients
|
N/A | |
Completed |
NCT03816956 -
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
|
Phase 3 | |
Active, not recruiting |
NCT01123681 -
Intubation and Extubation Over 48 Hours Mechanical Ventilation
|
N/A | |
Recruiting |
NCT04839653 -
Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria
|
N/A | |
Recruiting |
NCT03527992 -
Automated Oxygen Administration in Patients With Hypoxemic Pneumonia and Pleuropneumonia
|
N/A |